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Intestinal permeability can be assessed by monitoring renal excretion of orally administered
radioactively 51Cr-labeled ethylenediaminetetraacetic acid (51Cr-EDTA). Although consid-
ered safe, patient participation in using radio-labeled tracers is low. Here, we used orally
administered 52Cr-EDTA as non-radioactive alternative to assess intestinal permeability in
CD and analyzed the association with disease activity, disease location and gut microbial
dysbiosis.
Materials and methods
60 CD patients with low (n = 25) and increased (n = 35) fecal calprotectin levels (cut-off:
100 μg/g feces) ingested 20 mL 52Cr-EDTA (20 mmol/L) solution whereafter 24-h urine was
collected. Urinary 52Cr-EDTA concentrations were quantified using Inductively Coupled
Plasma Mass Spectrometry (ICP-MS). Fecal Enterobacteriaceae and Faecalibacterium
prausnitzii were quantified using FISH. Correlations between urinary 52Cr-EDTA excretion
and other parameters were established using nonparametric Spearman’s correlation coeffi-
cients (ρ).
Results
CD patients with increased fecal calprotectin levels (> 100 μg/g) demonstrated an elevated
urinary 52Cr-EDTA/creatinine ratio (772 vs. 636 μmol/mol, P = 0.132). Patients with primarily
colonic disease showed the highest 52Cr-EDTA excretion. Importantly, a positive correlation
was observed for the urinary 52Cr-EDTA/creatinine ratio and fecal calprotectin levels (ρ =
0.325, P < 0.05). Finally, urinary 52Cr-EDTA/creatinine ratio negatively correlated with the
relative abundance of Faecalibacterium prausnitzii (ρ = -0.221, P = 0.092), while positively
correlating with Enterobacteriaceae (ρ = 0.202, P = 0.126).
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Conclusions
Orally administered and renal excreted 52Cr-EDTA may be used to assess intestinal perme-
ability in CD and correlates with fecal calprotectin levels and bacterial species relevant to
CD. This test may improve non-invasive detection of disease exacerbations and help moni-
tor disease activity.
Introduction
In Crohn’s disease (CD), a disturbed balance between the gut mucosal immune system and intes-
tinal microbiota is intimately associated with diminished functioning of the intestinal barrier.
This barrier is instrumental in the protection against adhesion and infiltration of intraluminal
antigens into the underlying lamina propria, thereby maintaining a healthy gut. An important
functional and measurable feature of the gastro-intestinal barrier constitutes intestinal permeabil-
ity, which is influenced by both the gut microbiota and mucosal immunity. [1] Intestinal micro-
biota play a pivotal role in preserving gut epithelial barrier integrity. A strong link exists between
microbial dysbiosis and intestinal permeability. [2] Intestinal dysbiosis in CD is characterized by
increased numbers of (potentially) pathogenic bacteria, such as several members of the Enterobac-
teriaceae, and a decreased abundance of commensal bacteria, such as Faecalibacterium prausnitzii.
Decreased abundancy of Faecalibacterium prausnitzii is consistently observed in CD and is associ-
ated with increased inflammation and presumably disrupted intestinal barrier integrity. [3,4] Sim-
ilarly, Enterobacteriaceae, e.g. adherent-invasive Escherichia coli (AIEC), are known to possess
multiple pathogenic mechanisms that can lead to loss of intestinal barrier function. [5] These typi-
cal shifts of many bacterial species that are characteristic for CD dysbiosis are putatively related to
either gain or loss of intestinal epithelial barrier function (such as Faecalibacterium prausnitzii
and Enterobacteriaceae (e.g. Escherichia coli), respectively). [6,7]
An impaired intestinal permeability has been associated with many gastro-intestinal (GI)
and non-GI diseases. [1] In inflammatory bowel disease (IBD) research, there has been much
scientific interest in unraveling the complex association between a comprised gut wall integrity
and mucosal inflammation. Until now, however, it is not fully understood whether a defective
mucosal barrier in IBD promotes intestinal inflammation or that impaired barrier function is
secondary to the inflammatory process. [8,9] Nonetheless, the link between an increased intes-
tinal permeability and increased inflammatory activity is well-established. [10] There is also
increasing evidence that an increased intestinal permeability to macromolecules precedes the
onset of IBD and/or is a sign of subclinical disease activity. It may therefore be used as an early
predictor of clinical relapses in IBD patients. [11–14] This is illustrated by the fact that a subset
of clinically healthy first-degree relatives of Crohn’s disease patients are genetically predis-
posed to an increased intestinal permeability as compared to healthy controls. [15,16]
Despite this strong association, inflammatory disease activity has hitherto been monitored
inconsistently in clinical practice. Since a poor association exists between clinically active dis-
ease and observed endoscopic disease activity, non-invasive biomarkers have increasingly
been studied to predict active intestinal inflammation in CD. [17] For instance, biochemical
disease parameters such as the fecal calprotectin (FC) level and serum C-reactive protein
(CRP) are being widely utilized, since these markers correlate significantly with endoscopically
active disease. [18–20] In this study, we use fecal calprotectin levels as an accurate indirect
measure of inflammatory disease activity. [21,22]
Currently, orally administered tracers for intestinal permeability play no significant role in
monitoring disease exacerbations in CD, but may aid in the diagnostic accuracy of the
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currently available panel of non-invasive disease biomarkers and help predict CD disease
course. [19,23,24] The clinical utility and validity of these non-invasive tests for intestinal per-
meability are still not fully established. [1] An optimal intestinal permeability test should have
a number of properties. The test or marker is preferably sensitive, accurate, reproducible and
safe in order to assist in diagnosis and monitoring of disease flares. In addition, an in vivo
marker should be stable and inert, avoiding metabolism and degradation. [1,14]
Numerous studies have evaluated intestinal permeability using radioactively 51Cr-labeled
ethylenediaminetetraacetic acid (51Cr-EDTA). [11,12,25–33] However, these previously pub-
lished studies have been unable to establish a consistent correlation between 51Cr-EDTA-mea-
sured gut permeability and inflammatory disease activity, likely related to relatively small and
heterogeneous IBD study cohorts. Apart from this, most of these studies used the less preferred
radioactively 51Cr-labeled EDTA, followed by urinary analysis of gamma radiation. Conjointly,
its individual performance in clinical practice remains mostly unfeasible due to complex and
impractical detection methods. [1,29] A similar substance has recently been developed to eval-
uate intestinal permeability, in which the non-radioactive 52Cr isotope has been incorporated
into 52Cr-EDTA. This allows us to measure urinary 52Cr content in a safe, inexpensive and
precisely validated manner using the highly sensitive method of Inductively Coupled Plasma
Mass Spectrometry (ICP-MS). In contrast to radioactively labeled 51Cr-EDTA, only few stud-
ies have evaluated the performance of 52Cr-EDTA as a tracer for intestinal permeability. [34–
36] Cr-EDTA has proven to be a sensitive marker for human intestinal permeability, both in
health and disease. [35–39] Cr and EDTA form a stable and inert complex with one of the
highest affinity of known metals, without any physicochemical interactions that might be
expected to occur. [40,41] However, putative correlations between 52Cr-EDTA-measured
intestinal permeability and CD-specific disease parameters have not yet been established.
The aim of this study is to evaluate intestinal permeability through measuring 24-h urinary
excretion of orally administered 52Cr-EDTA in Crohn’s disease and its association with
inflammatory disease activity, disease localization and two key bacterial marker strains of CD
dysbiosis (Faecalibacterium prausnitzii and Enterobacteriaceae).
Materials and methods
Study population
Patients aged 18–65 years were recruited from March 2016 until April 2017 at the outpatient
IBD clinic of the University Medical Center Groningen (UMCG), Groningen, The Nether-
lands. All patients were diagnosed with Crohn’s disease (CD), according to clinical, endoscopic
and histopathological features. All patients were Caucasians and lived in the Northern part of
the Netherlands. Patients were divided into two groups based on fecal calprotectin levels as a
measure of inflammatory disease activity (using 100 μg calprotectin / gram feces as our cur-
rently used cut-off value for defining low and increased inflammatory disease activity). Stan-
dard demographic characteristics, including age, sex, body-mass index (BMI) and smoking
history, were recorded, as well as clinical parameters specific for CD, such as the Harvey-Brad-
shaw index (HBI), Montreal disease classification (including Age at diagnosis (A), Location of
disease (L) and the Behavior (B) of the disease) and current maintenance therapy. Disease loca-
tion was recorded from the most recently performed endoscopic evaluation, which was com-
pleted within 12 months of intestinal permeability testing. CD patients who were treated with
antibiotics 3 months prior to screening were not eligible for this study (to rule out an effect on
the microbiota composition). Furthermore, CD patients with severe disease activity, as
reflected by a HBI score > 12, or patients with an indication for remission-induction therapy,
were also excluded from this study. Routine laboratory examinations were performed,
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including hemoglobin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), leuko-
cyte count, thrombocyte count and creatinine levels. Fecal calprotectin levels were quantified
by enzyme-linked immunosorbent assays (ELISA) (BU¨HLMANN Laboratories AG, Switzer-
land) as a routine measurement in the UMCG. Samples were obtained after patients gave writ-
ten informed consent. This study has been approved by the Institutional Medical Ethical
Review Board (in Dutch: Medisch Ethische Toetsingcommissie, METc) of the University Med-
ical Center Groningen (UMC Groningen) (IRB no. 2014/291) and is in accordance with the
principles of the Declaration of Helsinki (2013).
52Cr-EDTA solution
The chromium-EDTA oral test solution consists of the active ingredients chromium(III)chlo-
ride (CrCl3.6H2O) and disodium edetate (C10H14N2Na2OH.2H2O), 70% sorbitol liquid crys-
talline and raspberry essence as sweeteners, 0.1 M NaOH for pH adjustment to reach a final
pH between 4.5–5.5, methylparahydroxybenzoate as preservative and purified water (accord-
ing to Ph. Eur. requirements) as solvent. The solution contained in total 400 μmol of 52Cr-
EDTA (20 mmol/L). Patients were instructed to drink the 52Cr-EDTA solution (20 mL)
together with a glass of water after an overnight fast. Subsequently, patients were asked to fast
for an additional 2 hours. Urine was collected for 24 hours from the moment of ingestion of
the 52Cr-EDTA test solution. Patients were also instructed to refrain from the intake of alco-
holic beverages or non-steroidal anti-inflammatory drugs (NSAID’s) two days prior to taking
the 52Cr-EDTA solution and during the 24-h urine collection period. Full details on the prepa-
ration of the 52Cr-EDTA solution were described previously. [42]
Analytical procedure
Urinary content of 52Cr was quantified using Inductively Coupled Plasma Mass Spectrometry
(ICP-MS), which is a highly sensitive analytical method for measuring various metals, includ-
ing chromium isotopes (Nexion 300X, Perkin Elmer, Medlon BV Enschede, The Netherlands).
[43] First, 24-h urine samples were 30-fold diluted with 0.5% HNO3 and 0.01% Triton X-100,
after which 103Rh was added as internal standard (IS). Subsequently, the sample analyte was
nebulized in a cyclonic spray chamber, atomized at extremely high temperature (ranging from
6,000–8,000˚C) and ionized using argon (Ar) plasma. Using a vacuum of ~ 20 mL/min, the
resulting ions were deflected into a quadrupole in which ions are separated based on their elec-
trical charge and mass, under the influence of an alternating electrical current. Finally, chro-
mium ions were detected via an electron multiplier. Urinary chromium (52Cr) was measured
while applying the kinetic energy discrimination (KED) mode, ensuring a general reduction
of polyatomic isobaric interferences (such as that of 40Ar12C). Final urinary 52Cr concentra-
tions (nmol/L) were divided by urinary creatinine concentrations (mmol/L) as correction for
hydration. Urinary creatinine levels were quantified by an enzymatic detection method follow-
ing supplier’s instructions (Roche Diagnostics, Roche Modular P Analyzer, Mannheim,
Germany).
Quantification of fecal bacteria using fluorescent in-situ hybridization
(FISH)
The quantification of Faecalibacterium prausnitzii and Enterobacteriaceae was performed as
previously described, with some minor modifications. [44] Patients were asked to provide
fecal samples at the time of the 24-h urine collection. Samples were mixed with 4.5 mL filtered
phosphate-buffered saline (PBS) and centrifuged at 700 g for 2–3 min. The resulting superna-
tant was 4-fold diluted with freshly-prepared 4% paraformaldehyde solution and stored
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overnight at 4˚C. Before counting, samples were coded and randomized by an independent
investigator. Serial dilutions were prepared to allow visual counting of total bacteria, Entero-
bacteriaceae and F. prausnitzii. Each dilution was spread over gelatin-coated glass slides and
dried at room temperature. After addition of the appropriate bacterial probes (see Table 1),
Eub338 (Rhodamine) for the total bacteria, Fprau645 (FITC) for F. prausnitzii and Ec1531
(CY3) for Enterobacteriaceae, slides were hybridized overnight at 50˚C. [45–47] In each glass
slide well, 25 fields were manually quantified using fluorescent microscopes (Leica 2 or Olym-
pus BH20 at 100X magnification). Bacteria were quantified using two different filters, FITC or
CY3, based on the probe colour. Based on the absolute bacterial counts, the relative percentage
of each bacterial group was calculated.
Statistics
Characteristics of the study population were shown as proportions (%, n), means ± standard
deviations (SD) or medians with interquartile range (IQR), as appropriate. Normality testing
was performed using Kolmogorov-Smirnov tests. Distributions of urinary 52Cr-EDTA/Cr
excretion were presented as median ± interquartile ranges (IQR) and presented in boxplots
(10th-90th percentiles) grouped by inflammatory disease activity, as determined by the fecal
calprotectin level (using 100 μg/g feces as cut-off value). Differences between groups were
tested using the independent sample t-test or Mann-Whitney U-test, as appropriate. Partial
correlations between urinary 52Cr-EDTA/creatinine ratio and other parameters were per-
formed using the nonparametric Spearman’s correlation coefficient (ρ). Associations between
correlated parameters were visualized in scatter plots with smoothed curves. Smoothing was
empirically applied by nonlinear regression using 2nd order polynomial functions with 1/y2
weighting. Statistical analyses were performed using SPSS Statistics 23.0 for Windows. P-
values� 0.05 were considered as statistically significant.
Results
Study cohort characteristics are shown in Table 2. Crohn’s disease (CD) patients with low
fecal calprotectin levels (n = 25) had a mean age of 44.1 ± 13.3 years and consisted of 8 males
(32.0%) and 17 females (68.0%), while patients with increased fecal calprotectin levels (n = 35)
had a mean age of 40.5 ± 12.2 years and consisted of 10 males (28.6%) and 25 females (71.4%).
Patients with increased levels of fecal calprotectin showed significantly elevated white blood
cell counts (WBC) (P< 0.05) and erythrocyte sedimentation rates (ESR) (P< 0.05). CD
patients with an increased level of fecal calprotectin had a significantly lower alcohol consump-
tion as compared to CD patients with low fecal calprotectin levels (P< 0.01). No significant
differences were observed for any other cohort characteristic. Also, clinical disease activity, as
measured by the Harvey-Bradshaw Index (HBI), was not significantly different between
patients with either low or increased fecal calprotectin levels. In the total study cohort, median
HBI score was 3 (IQR: 1–5), indicating that the majority of patients were in clinical remission
at the time of inclusion.
Table 1. Bacterial probes used in the fluorescent in-situ hybridization (FISH).
Target Probe Label Sequence 3’ > 5’
Total bacteria Eub338 Rhodamine TGAGGATGCCCTCCGTCG
F. prausnitzii Fprau645 FITC CAAAAAGAACTCATCACGTCTCC
Enterobacteriaceae Ec1531 CY3 ACTACTGCTCCGTGATGCCAC
https://doi.org/10.1371/journal.pone.0211973.t001
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Urinary 52Cr-EDTA/creatinine excretion proportionally increases with
fecal calprotectin levels
Distributions of the 24-h urinary 52Cr-EDTA/creatinine ratio among both groups are shown
in Fig 1A. CD patients with increased fecal calprotectin levels showed a trend of elevated
Table 2. Characteristics of Crohn’s disease patients (n = 60) with fecal calprotectin levels indicative of remissive disease (< 100 μg/g) and increased disease activity
(> 100 μg/g). Data are presented as numbers (n (%)), mean ± SD or median [IQR]†.
Characteristics FC < 100 μg/g (n = 25) FC > 100 μg/g (n = 35) P-value
Age (years) 44.1 ± 13.3 40.5 ± 12.2 0.431
Male gender 8 (32.0) 10 (28.6) 0.783
BMI (kg/m2) 25.6 ± 4.5 24.3 ± 5.4 0.233
Active smoking 5 (20.0) 7 (20.0) 1.000
Alcohol consumption (g/day) 3.6 [0.9;11.1] 0.8 [0.1;2.6] 0.009��
Ileocecal resection 11 (44.0) 13 (37.1) 0.606
HBI 0.313
Remission (< 5) 17 (68.0) 25 (71.4)
Mild disease (5–7) 6 (24.0) 4 (11.4)
Moderate disease (8–12) 2 (8.0) 6 (17.1)
Maintenance medication 0.936
None 7 (28.0) 8 (22.9)
Thiopurines 5 (20.0) 9 (25.7)
Mesalamine 3 (12.0) 6 (17.1)
TNF-antagonists 7 (28.0) 9 (25.7)




A1 (< 17 yr) 4 (16.0) 5 (14.3)
A2 (17–40 yr) 15 (60.0) 26 (74.3)
A3 (> 40 yr) 6 (24.0) 4 (11.4)
Montreal, Localization 0.476
L1 (ileal) 12 (48.0) 12 (34.3)
L2 (colonic) 4 (16.0) 5 (14.3)
L3 (ileocolonic) 9 (36.0) 18 (51.4)
Montreal, Behavior 0.642
B1 (non-stricturing, non-penetrating) 11 (44.0) 18 (51.4)
B2 (stricturing) 9 (36.0) 13 (37.1)
B3 (penetrating) 5 (20.0) 4 (11.4)
Laboratory values
CRP (mg/L) 0.9 [0.5;3.3] 2.6 [0.9;5.0] 0.052
ESR (mm/h) 8.0 [3.0;18.0] 13.0 [9.0;27.0] 0.028�
WBC (x109/l) 6.4 ± 1.6 7.8 ± 2.2 0.013�
FC (μg/g) 45 [40;67] 360 [175;760] 0.000���
Thrombocytes (x109/l) 288 ± 82 287 ± 67 0.776
Creatinine (μmol/l) 75 ± 15 71 ± 11 0.245
†FC, fecal calprotectin; BMI, body mass index; HBI, Harvey Bradshaw Index; TNF, tumor necrosis factor; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate;
WBC, white blood cell count. Differences between groups were tested using the independent sample t-test or Mann-Whitney U-test for continuous variables and the
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urine-excreted 52Cr-EDTA/creatinine (771.8 μmol/mol (IQR: 472.4–1005.9) vs. 636.4 μmol/
mol (IQR: 365.0–843.4), P = 0.132). Importantly, we observed a significant correlation between
Fig 1. The relationship between levels of urinary 24-h 52Cr-EDTA/creatinine excretion and fecal calprotectin. (A) Distribution of urinary 52Cr-EDTA/creatinine
excretion in patients with low (blue,< 100 μg/g) and increased (red,> 100 μg/g) fecal calprotectin levels, shown in boxplots. (B) Urinary 52Cr-EDTA/creatinine excretion
significantly correlates with fecal calprotectin levels (ρ = 0.325, P< 0.05), as represented by the red smoothed curve.
https://doi.org/10.1371/journal.pone.0211973.g001
Fig 2. Urinary 24-h excretion of 52Cr-EDTA/creatinine for different subgroups of CD patients according to the
Montreal classification of disease localization. No significant differences were observed between any groups
(P> 0.05).
https://doi.org/10.1371/journal.pone.0211973.g002
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urinary 52Cr-EDTA/creatinine excretion and fecal calprotectin levels (ρ = 0.325, P< 0.05, Fig
1B), while controlling for gender, disease localization, ileocecal resection status and alcohol
consumption.
Urinary 52Cr-EDTA/creatinine excretion is highest in CD patients with
solely colonic disease
No significant differences in 24-h urinary excretion of 52Cr-EDTA/creatinine were observed
for subgroups of CD patients with different disease localization according to the Montreal clas-
sification (P = 0.270, Fig 2). Still, CD patients with solely colonic disease showed the highest
median urinary 52Cr-EDTA/creatinine excretion (791 μmol/mol (IQR: 632–1088), n = 9),
whereas median excretion in patients with ileal involvement was lower (ileal disease:
472 μmol/mol (IQR: 312–821), n = 24; ileocolonic disease: 676 μmol/mol (IQR: 417–1006),
n = 27, P = 0.093).
Correlation analysis between urinary 52Cr-EDTA/creatinine excretion and
relative abundances of CD-associated bacterial species
The absolute and relative abundance of two CD-associated bacteria, F. prausnitzii and Entero-
bacteriaceae, was quantified by FISH analysis in fecal samples of all patients (see S1 Fig for rep-
resentative fluorescence microscopy images and S1 Table for quantifications). Among CD
patients with below-median and above-median 52Cr-EDTA/creatinine excretion, there were
no significant differences detected in relative abundances (%) of F. prausnitzii and Enterobac-
teriaceae. Interestingly, we observed a borderline non-significant negative correlation between
24-h urinary 52Cr-EDTA/creatinine excretion and relative numbers of F. prausnitzii (ρ =
-0.221, P = 0.092, Fig 3A). In contrast, a moderately positive correlation, though non-signifi-
cant, was found between 24-h urinary 52Cr-EDTA/creatinine excretion and relative numbers
of Enterobacteriaceae species (ρ = 0.202, P = 0.126, Fig 3B).
Fig 3. Correlations of 24-h urinary excretion of 52Cr-EDTA/creatinine with the relative abundances of key bacterial species in the diseased gut, as
represented by the red smoothed lines. (A) A negative correlation (ρ = -0.221, P = 0.092) is observed between the relative abundance (%) of F. prausnitzii and
urinary 52Cr-EDTA/creatinine excretion, though this was not statistically significant. (B) A positive correlation (ρ = 0.202, P = 0.126) is observed between the
relative abundance (%) of Enterobacteriaceae and urinary 52Cr-EDTA/creatinine excretion, though this correlation was also not statistically significant.
https://doi.org/10.1371/journal.pone.0211973.g003
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Discussion
In this study, we show that increased urinary excretion of orally administered 52Cr-EDTA sig-
nificantly correlates with elevated levels of fecal calprotectin in CD patients. Furthermore, CD
patients with solely colonic disease activity show elevated 52Cr-EDTA/creatinine urinary
excretion as opposed to CD patients having only an affected ileum. In addition, we observed
an interesting trend of a negative association between 52Cr-EDTA-measured intestinal perme-
ability and relative numbers of F. prausnitzii, whereas a trend of a positive association was
observed between Enterobacteriaceae counts and urinary 52Cr-EDTA excretion. These correla-
tions, though they lacked statistical significance, may suggest the possibility of a relationship
between intestinal permeability and intestinal dysbiosis. Overall, our findings suggest that the
measurement of urinary 52Cr-EDTA excretion might serve as novel approach for determining
compromised intestinal permeability, as is characteristic for severe CD.
Chromium-EDTA has been widely used as marker for intestinal permeability, due to its
high sensitivity and the stability of the Cr-EDTA complex. [35] However, most studies used
the radioactive form 51Cr-EDTA that may have adverse effects due to radiation exposure.
Here, we assessed the non-radioactive and inert 52Cr-EDTA to evaluate intestinal permeability
in CD, in combination with quantifying urinary 52Cr by highly-sensitive ICP-MS. This method
is particularly useful in detecting metal isotopes at very low concentrations in a safe, inexpen-
sive and rigorously validated manner (Nexion 300X, Perkin Elmer, Medlon BV Enschede, The
Netherlands). The currently applied ICP-MS method appeared to be highly sensitive in detect-
ing 52Cr, with an internally determined lower limit of quantification (LLOQ) of 9.8 nmol/L.
The average concentration of endogenous chrome in individuals in human blood and urine
lies in the range of 0.1–0.5 μg/L (1.9–9.6 nmol/L), which falls below the LLOQ of ICP-MS and
is thus negligibly small. For instance, the lowest individual value measured in our study cohort
was 1352 nmol/L. [48]
This study assessed the 52Cr-EDTA intestinal permeability test in a relatively large study
cohort of CD patients. Interestingly, the majority of these patients (70%) were in clinical
remission according to the HBI, but still show a large variation in 52Cr-EDTA-measured intes-
tinal permeability. Our study cohort is larger and less heterogeneous than all previous per-
formed studies that have evaluated the potential application of Chromium-EDTA-measured
intestinal permeability in IBD. [11,12,25–33] Patient participation within our study was high,
due to the non-invasive and non-radioactive nature of this test. However, careful test monitor-
ing was required since several factors could affect urinary excretion levels of 52Cr-EDTA, such
as adherence to the experimental protocol and the duration of urine collection. [49] Also, in
the present study cohort, no endoscopic disease activity data were available, which are prefer-
entially used as representative of inflammatory disease activity in CD. Alternatively, we used
the fecal calprotectin level as surrogate marker for CD disease activity. [19,20,50–52] Here,
fecal calprotectin levels were directly related to 52Cr-EDTA-measured intestinal permeability,
which has previously not been established.
Few studies specifically focused on the association between increased 51Cr-EDTA-mea-
sured intestinal permeability and inflammatory disease activity. [26,32,53] Hitherto, Berstad
et al. found a significant correlation between 5-h urinary 51Cr-EDTA excretion and calprotec-
tin levels in gut lavage fluid of IBD patients. [53] Another study observed an association
between increased 51Cr-EDTA-measured intestinal permeability and serum levels of acute-
phase reactants and 111In-labeled leukocyte scans. [32] In UC, a significant correlation
between 51Cr-EDTA-measured intestinal permeability and endoscopic disease activity was
demonstrated. [26] In CD, it has been shown that anti-TNF treatment attenuates mucosal
inflammation and also improves intestinal integrity measured by orally administered 51Cr-
52Cr-EDTA intestinal permeability in Crohn’s disease patients
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EDTA. [54] Although the relationship between disease activity and Cr-EDTA-measured in-
testinal permeability seems to be well-established, studies show weak comparability because of
various study designs, different intestinal permeability tracers and varying time intervals. Fur-
thermore, it is difficult to clearly demonstrate this relationship since many factors are known to
affect intestinal permeability, such as disease localization, surgical history, alcohol consumption,
medication use, commensal bacteria and many dietary components. [55] As a consequence, the
extent of this relationship remains inconclusive. In addition, all the previously mentioned stud-
ies are remarkably contradictory as to the primary intestinal location and degree of increased
51Cr-EDTA bowel passage. [25–29] In our study cohort, CD patients with exclusively colonic
disease activity showed a higher median urinary 52Cr-EDTA/creatinine excretion as compared
to patients with ileal involvement, though non-significantly. Similarly, we could not demon-
strate any statistically significant differences in intestinal permeability between three different
subgroups of disease localization (i.e. ileal, colonic or ileocolonic disease).
Until now, it remains unclear whether increased intestinal permeability is secondary to sub-
clinical mucosal inflammation in CD or vice versa. [56,57] Accumulating evidence suggests
that increased intestinal permeability may be the consequence of a genetically pre-existing epi-
thelial barrier abnormality in certain individuals that predisposes them to the onset of intesti-
nal inflammation. [58] Various studies have shown that a subset of clinically healthy first-
degree relatives of Crohn’s disease patients show increased intestinal permeability as compared
to healthy controls. [15,16] Moreover, it has been hypothesized that impaired intestinal per-
meability may already be apparent long before any mucosal inflammation is present and
could be predictive of clinical relapse. In addition, another study demonstrated that in first-
degree relatives of CD patients subclinical intestinal inflammation is present, reflected by an
increased fecal calprotectin level. [59] In our study, we found a significant correlation between
intestinal inflammatory disease activity (as represented by fecal calprotectin levels) and intesti-
nal permeability (as measured by urinary 52Cr EDTA excretion). Overall, this indicates that
52Cr-EDTA-measured intestinal permeability might be particularly useful in defining the first
stages of development of Crohn’s disease in a subgroup of unaffected, genetically susceptible
individuals.
CD patients typically demonstrate a decreased gut microbiota diversity as compared to
healthy individuals. [60] An important observation in CD is the reduction in the commensal
anaerobic, butyrate-producing bacterium F. prausnitzii, as well as an increased number of
Enterobacteriaceae (e.g. Escherichia coli). [3,6,61] In the present study, we observed a negative
non-significant relationship between 52Cr-EDTA-measured intestinal permeability and the
relative abundance of F. prausnitzii, while a positive non-significant relationship was observed
between the relative abundance of Enterobacteriaceae and urinary 52Cr-EDTA excretion in
CD patients. These interesting associations (though moderate and non-significant) support
the existence of a link between the gut microbiota composition and the integrity of the intesti-
nal barrier. Future studies are needed to further elucidate this relationship, for example
through in vitro modeling of host-microbe interactions using bacteria-gut epithelial co-culture
systems. [6] In this way, the influence of specific bacterial species on epithelial markers for
intestinal permeability may give more fundamental insight into this complex association.
In conclusion, we show that a moderate positive correlation exists between 52Cr-EDTA-
measured intestinal permeability and fecal calprotectin levels. In addition, we demonstrate
interesting, though non-significant correlations between intestinal permeability and two key
gut bacterial species, suggesting the possibility of a relationship between dysbiosis and perme-
ability. Future studies should primarily focus on the utility of orally administered 52Cr-EDTA
as measure of intestinal permeability in relation to endoscopic disease activity and its potential
role as predictor of CD disease exacerbations.
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Supporting information
S1 Fig. Fluorescence in situ hybridization (FISH) experiments quantify the absolute and
relative amounts of selected bacteria in fecal samples. Paraformaldehyde-fixed fecal samples
were hybridized with specific fluorescent oligonucleotide probes and visualized with an Olym-
pus BH2 epifluorescence microscope. Images are shown as examples and are taken from ran-
dom samples not related to each other. (A) Epifluorescent images of a hybridization with a
Rhodamine-labeled Eub338 probe specific for almost all bacteria at a 1600 x dilution of a fecal
patient sample. (B) Hybridization with a FITC-labeled Faecalibacterium prausnitzii-specific
probe Fprau645 of a 160 x diluted fecal sample. (C) Hybridization with the Fprau645 probe at
40 x dilution of the fecal sample. (D) Hybridization with the CY3-labeled Enterobacteriaceae-
specific probe Ec1531 at a 40x dilution of the fecal sample. Bar, 20 μm.
(TIF)
S1 Table. Median numbers of F. prausnitzii and Enterobacteriaceae per gram of feces and
their relative abundances (%) to total microbiota (Eub338). Data are shown for the total
study cohort (n = 60), and for subgroups of CD patients with below- and above-median uri-
nary 52Cr-EDTA/creatinine excretion. Data are presented as median (IQR).
(DOCX)
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